|Bid||56.25 x 100|
|Ask||59.48 x 200|
|Day's Range||55.51 - 57.36|
|52 Week Range||33.97 - 58.11|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.95%|
Biotech sector stocks surged after the election, but pulled back when Trump targeted drug companies.
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn't meet its primary endpoint. Horizon stock fell 22.5% that day.